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BACKGROUND. Progressive aging- and inflammation-associated fibrosis effectively
remodels the extracellular matrix (ECM) to increase prostate tissue stiffness and reduce ure-
thral flexibility, resulting in urinary flow obstruction and lower urinary tract symptoms
(LUTS). In the current study, we sought to test whether senescence-accelerated mouse prone
(SAMP)6 mice, which were reported to develop prostatic fibrosis, would also develop LUTS,
and whether these symptoms would be exacerbated by diet-induced obesity and concurrent
Type 2 Diabetes Mellitus (T2DM).
METHODS. To accomplish this, SAMP6 and AKR/J background strain mice were fed regu-
lar mouse chow, low fat diet chow, or high fat diet chow for 8 months, then subjected to
glucose tolerance tests, assessed for plasma insulin levels, evaluated for urinary voiding func-
tion, and assessed for lower urinary tract fibrosis.
RESULTS. The results of these studies show that SAMP6 mice and AKR/J background
strain mice develop diet-induced obesity and T2DM concurrent with urinary voiding dys-
function. Moreover, urinary voiding dysfunction was more severe in SAMP6 than AKR/J
mice and was associated with pronounced prostatic and urethral tissue fibrosis.
CONCLUSIONS. Taken together, these studies suggest that obesity, T2DM, lower urinary
tract fibrosis, and urinary voiding dysfunction are inextricably and biologically linked.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is one of the
most common benign proliferative conditions associ-
ated with aging in men. BPH is a chronic, progressive
disease of the prostate which conservatively affects
30–35% of men aged 60 or older and results in a sig-
nificantly negative impact on quality of life [1–3]. This
negative impact is due to various co-morbidities that
develop concurrently with BPH that collectively pro-
duce lower urinary tract symptoms (LUTS) character-
istic of lower urinary tract dysfunction, or LUTD.
LUTD is itself a progressive disorder that is manifest-
ing as urgency, nocturia, urinary frequency, weak
urinary stream, and incomplete bladder emptying.
Without effective treatment, LUTD can lead to blad-
der outlet obstruction (BOO) and subsequent bladder
wall hypertrophy, increased bladder mass, and blad-
der dysfunction manifest as acute urinary retention,
recurrent urinary tract infections, bladder stones, and,
eventually, renal dysfunction [4]. Type 2 Diabetes
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Mellitus (T2DM), a chronic disorder of carbohydrate,
fat, and protein metabolism, is an important cause of
morbidity and mortality in the US. Like BPH/LUTD,
T2DM is associated with older age, as well as with
obesity, a family history of diabetes, a history of ges-
tational diabetes, impaired glucose metabolism, phys-
ical inactivity, and race/ethnicity [5]. The National
Institute of Diabetes and Digestive and Kidney Dis-
eases (NIDDK) reports that T2DM currently affects
25.8 million people of all ages, or 8.3%, of the entire
US population. In 2010, the most recent year for
which there is data, 10.9 million (26.9%) of all US resi-
dents aged 65 years or older had T2DM, and 1.9 mil-
lion people aged 20 years or older were newly
diagnosed with T2DM [6].
There is growing evidence that LUTD and T2DM
are linked etiologically and biologically. Diet-induced
obesity has been identified as a risk factor for both
T2DM and LUTS in men [7,8]. Conversely, reversion
of obesity through weight loss is linked with reduc-
tion of symptoms associated with diabetes and LUTS
[9]. Several epidemiologic studies that have examined
the association between LUTS and diabetes also sug-
gest that LUTS may occur more frequently among
men with diabetes, with an estimated 25% to nearly
twofold increased risk of LUTS in men with diabetes
[10–13]. In addition, among 9,856 men with clinically
diagnosed BPH, the presence of diabetes (13%) was
associated with increased LUTS severity, affecting
voiding more than storage function. Patients with
BPH and diabetes had a significantly higher baseline
International Prostate Symptoms Score (IPSS) and a
significantly lower maximal urinary flow rate (Qmax)
that those without diabetes (both P < 0.001) [12].
A possible explanation for an association between
BPH and diabetes beyond that explained by comor-
bidity due to age is that the two disease states can
cause at least partially similar urological symptoms.
However, the underlying biological mechanisms pro-
ducing these symptoms may be different. Dib et al.
studies 50 consecutive diabetic patients, 23 (46%) of
whom had concurrent BOO symptoms based on pres-
sure/flow urodynamic measurements. However, no
significant differences in IPSS or prostate volume
were apparent between diabetic patients with BOO
compared to those without obstructive symptoms.
These data suggest little, if any, association between
BOO in diabetic patients with prostate enlargement
and LUTS [14]. Similarly, a multiethnic community-
based study demonstrated positive associations be-
tween diabetes and irritative LUTS and nocturia, but
not between diabetes across measures more specific
to BPH (i.e., prostate volume, PSA, and peak urinary
flow rate) [15]. Taken together, these studies suggest
that the presence of diabetes may be less related to
prostate growth and more related to the dynamic
components of lower urinary tract function.
We have previously reported that progressive ag-
ing- and inflammation-associated fibrosis effectively
remodels the extracellular matrix (ECM) to increase
prostate tissue stiffness and reduce urethral flexibili-
ty, resulting in urinary flow obstruction and LUTS
[16]. These observations suggest that tissue fibrosis
adversely changes the dynamic of lower urinary tract
function. In the current study, we sought to test these
associations in a mouse model of accelerated aging
subjected to diet-induced obesity and T2DM. Specifi-
cally, the studies reported here were designed to test
whether senescence-accelerated mouse prone
(SAMP)6 mice, which were reported to develop pros-
tatic fibrosis [17–20], would also develop LUTS, and
whether these symptoms would be exacerbated by
diet-induced obesity and concurrent T2DM. The
results of these studies show that SAMP6 mice and
AKR/J background strain mice develop diet-induced
obesity and T2DM concurrent with urinary voiding
dysfunction. Moreover, urinary voiding dysfunction
is more severe in SAMP6 mice and is associated with
pronounced prostatic and urethral fibrosis. Taken to-
gether, these studies suggest that obesity, T2DM, low-
er urinary tract fibrosis, and urinary voiding
dysfunction are inextricably and biologically linked.
MATERIALSANDMETHODS
MouseStrains andMaintenance
Two related mouse strains were used in these stud-
ies: SAMP6 and the AKR/J background strain. Colo-
nies were established from eight females and four
males per strain purchased at 6 weeks of age (Harlan
Laboratories, Indianapolis, IN). At 6–8 weeks of age,
25 mice each SAMP6 and AKR/J were fed the follow-
ing diets: high fat diet (HFD) containing 60% calories
from fat, 20% protein, and 20% carbohydrates (58Y1,
Test Diet, Richmond, IN); low fat diet (LFD) contain-
ing 10.2% calories from fat, 18.3% protein, and 71.5%
carbohydrates (58Y2, Test Diet, Richmond, IN), or
regular diet (RD) grain-based mouse chow containing
13.50% calories from fat, 28.50% protein, and 58% car-
bohydrates (#5001, Lab Diet, St. Louis, MO). The mice
were fed daily with fresh high, low fat or regular
chow (5 g/day) for 8 months. Mice were housed in
the Unit for Animal Laboratory Medicine (ULAM) fa-
cility at the University of Michigan under enriched
conditions at a constant temperature (22–238C) with a
12/12 hr light/dark cycle and optimal humidity and
free access to tap water and food ad libitum. The
body weights of all mice were measured once during
the first week of the month for eight consecutive
months. All animal procedures were performed using
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protocols approved by the University Committee on
Use and Care of Animals (UCUCA).
OralGlucoseToleranceTest
Oral glucose tolerance tests (OGTTs) were carried
out just prior to the termination of the study. OGTTs
were measured in 10 mice each fed HFD or LFD from
each mouse strain (a total of 40 mice). The OGTTs
were performed in semi-fasted mice, for example, on
the day preceding the test, mice fasted for 5 hr, start-
ing at 8:30 am. Glucose 50% was given around
1:30 pm via oral gavage at 2.0 g/kg. Blood samples
were collected prior to and after the gavage at the
time of 0, 15, 30, 60, and 120 min after via tail vein
bleeding. The oral glucose load was given by gavage
via a gastric tube connected to a syringe to ensure
accurate dosing. Blood glucose concentration was
measured at all-time points using a glucometer (Acu-
check, Roche).
Plasma InsulinMeasurement
Blood samples were collected in tubes containing
EDTA to avoid clotting and placed on ice until they
were centrifuged at 3,000 rpm and frozen at 808C
until plasma content measurements were conducted.
Plasma levels of insulin were determined using milli-
pore rat/mouse insulin using a commercially avail-
able insulin ELISA kit [12]. Animals were restrained
repeatedly for less than a minute each time while
blood samples were collected.
DeterminationofUrinaryVoiding Function
The urinary voiding function of all of mice were
measured once during the first week of the month for
eight consecutive months. The urinary voiding func-
tion was determined using a filter paper assay, as pre-
viously described with some modification [21]. For
these studies, all mice in a single cage (4–5 mice) were
placed into a urine monitoring cage. The bottom of
this cage was fitted with a wire mesh beneath which
was Whatman Grade 3 filter paper. The mice were
left in the monitoring cage for 5 hr, after which the
filter paper was collected. Urine which had soaked
into the filter paper was strongly fluorescent under
UV light and was easily visualized under those condi-
tions. The pattern of urine spots was independently
determined by two different observers (M. G.-K. and
J. R.-N.) using a modification of previously described
methods [21]. Each voiding pattern was given a grade
of 1–5 depending upon the size and number of urine
spots such that a score of 1 indicated the observation
of single, large urine spots (no voiding dysfunction)
and a score of 5 indicated the observation of many
small, scattered urine spots (obstructive voiding dys-
function). The data from the two independent observ-
ers was averaged and statistically analyzed.
TissueProcessingandHistological Evaluation
Mouse lower urinary tracts were harvested at
10 months of age (after 8 months of feeding with RD,
HFD, or LFD). Male mice were euthanized by CO2
asphyxiation in accordance with institutional guide-
lines. Lower urinary tracts consisting of bladder, pros-
tatic and pelvic urethra, prostate and seminal vesicles
were ressected en bloc and placed in ice cold saline.
Peripheral adipose tissue was removed and distal
prostate lobe aspects were teased apart to liberate
each from its attachments to other prostate lobes, sem-
inal vesicle, and urethra. To preserve proximodistal
orientation of seminal vesicle and prostate ducts, low-
er urinary tract tissues were fixed intact by orienting
them on their lateral surfaces, sandwiching them be-
tween histology sponges and fixing them overnight at
48C in 10% neutral buffered formalin. Histology
sponges were removed and tissues were dehydrated
through an ethanol series, cleared in xylene and infil-
trated with paraffin. Tissue sections were subjected to
hematoxylin/eosin (H/E) staining and assessed for
histopathology or subjected to Masson’s Trichrome
staining to assess collagen content. Prostate wet
weight was not measured because of inherent vari-
ability in prostate morphology in the different strains.
CollagenContent
Collagen content was determined using the meth-
odology described previously [16,22]. Briefly, Mas-
son’s Trichrome stained tissue sections were digitally
imaged using a PathScan Enabler IV and color seg-
mented using a subprogram within MATLAB
(R2010a; MathWorks, Natick, MA) that separates and
quantifies color elements from trichrome images, per-
mitting quantitation of blue-stained areas correspond-
ing to extracellular collagen. Using the area of a single
tissue section as the denominator, this approach pro-
vides a means to calculate the portion of this area that
is made up by mature extracellular collagen I (the nu-
merator), hence, the percentage of extracellular colla-
gen type I (numerator/denominator  100) in that
tissue section. By extension, this method also permits
calculation of the percentage of the entire piece of tis-
sue that is made up of mature extracellular collagen I.
StatisticalAnalysis
Averages and standard deviations were calculated
and compared using two-tailed Students’ t-tests.
In all tests, P < 0.05 was considered statistically
significant.
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RESULTS
HighFatDiet-FedMiceDevelopObesity-Induced
Type 2DiabetesMellitus
Both SAMP6 (Fig. 1A,C) and AKR/J (Fig. 1B,D)
mice demonstrated cumulative weight gains of 1–2 g
and 5–7 g when fed a RD or LFD over an 8-month
period, respectively. In contrast, SAMP6 (Fig. 1A,C)
and AKR/J (Fig. 1B,D) mice almost doubled in body
weight, from 30 g at the initiation of a HFD to a total
body weight of 50–60 g (cumulative weight gain of
20–30 g), when fed a HFD over an 8-month period.
At the end of 8 months, SAMP6 and AKR/J mice
fed continuously either the LFD or HFD were sub-
jected to 2 hr OGTTs. The results of the OGTTs
showed that SAMP6 HFD-fed mice demonstrated the
highest blood glucose levels, which peaked at
420 mg/dl at 40 min, followed by SAMP6 LFD-fed
mice (300 mg/dl glucose), AKR/J HFD-fed mice
(220 mg/dl) and AKR/J LFD-fed mice (200 mg/dl)
(Fig. 2A). The average areas under the curve (AUCs)
demonstrated significantly higher blood glucose lev-
els for SAMP6 HFD-fed compared to LFD-fed mice
(P < 0.0003), and AKR/J HFD-fed compared to LFD-
fed mice (P < 0.03) (Fig. 2B). The AUCs also showed
that blood glucose levels were significantly higher for
SAMP6 HFD-fed compared to AKR/J HFD-fed
(P < 0.001) and for SAMP6 LFD-fed compared to
AKR/J LFD-fed (P < 0.04) mice. Plasma insulin levels
were determined concurrent with the blood glucose
levels. The results of these studies showed that plas-
ma insulin levels were significantly higher for SAMP6
compared to AKR/J HFD-fed mice (P < 0.001), for
SAMP6 HFD-fed compared to LFD-fed mice
(P < 0.001) and for AKR/J HFD-fed compared to
LFD-fed mice (P < 0.002) (Fig. 2C,D).
Taken together, these data suggest that both
SAMP6 and AKR/J HFD-fed mice developed hyper-
glycemia and insulin resistance (hyperinsulinemia)
consistent with T2DM concurrent with diet-induced
obesity.
HighFatDiet-FedMiceDevelopUrinaryVoiding
Dysfunction
Several epidemiologic studies have linked LUTS
with T2DM [9–12]. Therefore, we examined both
HFD-fed and LFD-fed mice for urinary voiding func-
tion. For these studies, all mice in a single cage (4–5
Fig. 1. High fat diet-induced obesity in SAMP6 and AKR/JMice.The graphs depict the cumulativeweight gain of SAMP6 (A) and AKR/J (B)
mice fedregularmouse chowdiet (RD), low fatdiet (LFD)orhigh fatdiet (HFD) for 8months.Mice fromboth strains fedRDorLFDgained1^
5 g over the 8-month period whereas those fed HFD virtually doubled in weight and gained 20^30 g over the same period. Photographs
depictrepresentativeSAMP6(C) andAKR/J (D)miceafter8monthsonLFDorHFDdietsasindicated.
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mice) were placed into a urine monitoring cage for
5 hr and the pattern of urine spots on the filter paper
visualized under UV light. The pattern of urine spots
was assessed using a modification of previously de-
scribed methods by two different observers and the
results averaged and statistically analyzed. As shown
in Figure 3A, the urinary voiding pattern was graded
on a scale of 1–5 depending upon the size and num-
ber of urine spots such that a score of 1 indicated the
observation of single, large urine spots (no voiding
dysfunction) and a score of 5 indicated the observa-
tion of many small, scattered urine spots (obstructive
voiding dysfunction). Urine voiding patterns were
assessed for SAMP6 and AKR/J mice after 7 and
8 months of continuous feeding on RD, LFD, or HFD.
Both SAMP6 and AKR/J mice demonstrated normal
urinary voiding patterns after 7 or 8 months continu-
ous RD-feeding. SAMP6 and AKR/J mice demon-
strated similar though slightly abnormal urinary
voiding patterns suggestive of mild obstruction at 7
and 8 months continuous LFD-feeding. Both SAMP6
and AKR/J mice demonstrated abnormal urinary
voiding patterns suggestive of moderate obstruction
for AKR/J mice and moderate/severe obstruction for
SAMP6 mice at 7 and 8 months continuous HFD-feed-
ing. The urine voiding scores for both SAMP6 and
AKR/J HFD-fed mice were significantly worse than
for LFD-fed (P < 0.008) and RD-fed mice (P < 0.001).
Further, SAMP6 urinary voiding dysfunction was sig-
nificantly worse (P < 0.001) than that of AKR/J mice
Fig. 2. SAMP6 and AKR/J mice HFD-fed mice develop hyperglycemia and insulin resistance consistent with T2DM. A: At the end of
8 months, SAMP6 and AKR/J mice fed continuously either the LFD or HFD were subjected to 2 hr oral glucose tolerance tests (OGTTs).
SAMP6HFD-fedmice demonstrated thehighestbloodglucose levels,whichpeakedat 420 mg/dl at 40 min, followedbySAMP6LFD-fedmice
(300 mg/dl glucose), AKR/J HFD-fedmice (220 mg/dl), and AKR/J LFD-fedmice (200 mg/dl).B: The average areas under the curve (AUCs)
demonstrated significantlyhigherbloodglucose levels for SAMP6HFD-fedcomparedtoLFD-fedmice (P < 0.0003), andAKR/JHFD-fedcom-
pared toLFD-fedmice (P < 0.03).TheAUCs also showed thatbloodglucose levelswere significantlyhigher for SAMP6HFD-fedcompared to
AKR/J HFD-fed (P < 0.001) and for SAMP6 LFD-fed compared to AKR/J LFD-fed (P < 0.04) mice.C: Plasma insulin levels were determined
concurrent with the blood glucose levels.D: Plasma insulin levels were significantly higher for SAMP6 compared to AKR/J HFD-fed mice
(P < 0.001), forSAMP6HFD-fedcomparedtoLFD-fedmice (P < 0.001) andforAKR/JHFD-fedcomparedtoLFD-fedmice (P < 0.002).
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at both 7 and 8 months continuous HFD-feeding
(Fig. 3B). In addition to dermatitis, both SAMP6 and
AKR/J HFD-fed mice exhibited acute urinary reten-
tion and were unable to void urine, requiring eutha-
nasia (Fig. 4A,B). The results of these studies
demonstrate that continuous feeding on a HFD was
associated with the acquisition of urinary voiding
dysfunction for both SAMP6 and AKR/J mice, but
the level of dysfunction was most severe for SAMP6
HFD-fed mice.
HFD-FedMiceExhibit LowerUrinaryTract Fibrosis
Previous studies from our group showed that the
peri-urethral prostate tissues from men with LUTS
were significantly stiffer (P ¼ 0.0016, r ¼ 0.82) and
demonstrated significantly higher collagen content
(P ¼ 0.0038, r ¼ 0.60) and lower glandularity than
those from men without LUTS [16]. These observa-
tions suggested that ECM deposition and fibrosis con-
tribute to urinary obstructive symptoms and LUTS.
Therefore, we examined the lower urinary tract tis-
sues of LFD-fed and HFD-fed mice for histopatholog-
ical evidence of fibrosis. Masson’s Trichrome stained
tissue sections of fixed and embedded mouse lower
urinary tracts (Fig. 5A) were digitally imaged and col-
or segmented using a subprogram within MATLAB
that separates and quantifies color elements from
images of stained tissues, permitting quantitation of
blue-stained areas corresponding to extracellular col-
lagen [16,23]. Because previous studies had suggested
that SAMP6 mice exhibited fibrosis of the dorsal lobe
[19] we specifically focused on analyzing the collagen
content of the dorsal lobe. Although the urethral re-
gion presented as a saggital, rather than the desired
coronal, cross-sectional area in these particular prepa-
rations of the lower urinary tract, these were also ana-
lyzed for collagen content. As shown in Figure 5B, the
prostatic dorsal lobes of SAMP6 (P < 0.001) and
AKR/J (P < 0.01) HFD-fed mice demonstrated 2–4
higher collagen content than those of LFD-fed mice
(P < 0.001). Similarly, the urethral regions of SAMP6
(P < 0.001) and AKR/J (P < 0.001) HFD-fed mice
(P < 0.003) demonstrated 2–4 higher collagen levels
than those of LFD-fed mice.
Fig. 3. Highfatdiet-fedmicedevelopurinaryvoidingdysfunction.
A:Theurinary voidingpatternwasgradedona scaleof1^5depend-
ingupon the size andnumberofurine spots such that a score of1in-
dicated the observation of single, large urine spots (no voiding
dysfunction) and a score of 5 indicated the observation of many
small, scattered urine spots (obstructive voiding dysfunction). B:
Graph depicts 95% confidence intervals for urine voiding patterns
for SAMP6 (black) and AKR/J (grapy) mice after 7 (diamond) or 8
(square) months of continuous feeding on RD, LFD, or HFD diets.
BothSAMP6andAKR/Jmicedemonstratednormalurinary voiding
patterns after 7 or 8 months continuous RD-feeding. SAMP6 and
AKR/Jmice demonstrated similar though slightly abnormalurinary
voiding patterns suggestive of mild obstruction at 7 and 8 months
continuous LFD-feeding.BothSAMP6andAKR/Jmice demonstrat-
ed abnormal urinary voiding patterns suggestive of moderate ob-
struction for AKR/J mice and moderate/severe obstruction for
SAMP6 mice at 7 and 8 months continuous HFD-feeding that was
significantly worse than LFD-fed (P < 0.008) and RD-fed mice
(P < 0.001).Further,SAMP6urinary voidingdysfunctionwas signifi-
cantly worse (P < 0.001) than that of AKR/J mice at both 7 and
8monthscontinuousHFD-feeding.
Fig. 4. High fat diet-fedmice develop urinary retention and der-
matitis.The majority of SAMP6 and AKR/J HFD-fed mice develop
urinary retention (A) evident as inflated bladders (B, arrow, HFD
mouse) concurrent with urinary voiding dysfunction. A smaller
number of HFD-fed mice also developed chronic dermatitis (A).
Epididymal fat pads are notably enlarged in SAMP6 HFD-fed mice
(B,asterisks).
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Histopathological analysis of serial H/E stained
sections to those analyzed for collagen content dem-
onstrated peri-glandular prostatic fibrosis in SAMP6
HFD-fed mice (Fig. 5C, i and ii) and milder focal
fibroplasia in SAMP6 LFD-fed mice (Fig. 5C, iii and
iv). These differences in peri-glandular fibrosis were
more evident in SAMP6 HFD-fed than LFD-fed mice,
and these differences trended towards, but did not
reach, statistical significance (P ¼ 0.10) (Table I). Epi-
thelial hyperplasia was more evident in AKR/J HFD-
fed and LFD-fed mice than SAMP6 mice, but the ob-
served differences between diets (for either strain)
were not significant (Table I). The anterior prostates
appeared normal in both HFD-fed and LFD-fed
SAMP6 and AKR/J mice, as did the seminal vesicles
though some mild epithelial hyperplasia was ob-
served for AKR/J (not shown). Notably, significantly
higher levels of brown adipose tissue (BAT) than
white adipose tissue (WAT) was evident in SAMP6
LFD-fed compared to HFD-fed mice (P ¼ 0.005)
(Table I) (Fig. 5D). A similar trend was noted for
AKR/J LFD-fed compared to HFD-fed mice but these
differences did not reach significance (Table I).
DISCUSSION
Previous studies from our research group showed
that lower urinary tract fibrosis is associated with
moderate/severe LUTS in American men [16]. The
studies reported here now show that SAMP6 mice
and AKR/J background strain mice develop diet-in-
duced obesity and T2DM concurrent with urinary
voiding dysfunction and pronounced lower urinary
tract fibrosis. Taken together, these studies suggest
Fig. 5. HFD-fedmiceexhibitlowerurinary tract fibrosis.A:Masson’sTrichromestainedtissue sectionsof fixedandembeddedmouselower
urinary tracts were digitally imaged and color segmented using a subprogramwithin MATLAB that separates and quantifies color elements
from images of Masson’sTrichrome stained tissues, permitting quantitation of blue-stained areas corresponding to extracellular collagen
[16,23].B:Thepercentcollagencontentof theprostatic dorsal lobes of SAMP6 (P < 0.001) andAKR/J (P < 0.01)HFD-fedmice demonstrated
2^4highercollagenlevels than thoseofLFD-fedmice (P < 0.001). Similarly, theurethralregionsofSAMP6 (P < 0.001) andAKR/J (P < 0.001)
HFD-fedmice (P < 0.003) demonstrated2^4 highercollagen levels than those of LFD-fedmice.C: Photomicrographs (20, i, iii; 40, ii, iv)
of serialhematoxylin/eosinstainedsections to thoseanalyzedforcollagencontentdemonstratedperi-glandularprostatic fibrosis (redarrows)
in SAMP6 HFD-fedmouse#68 (i, ii) andmilder focal fibroplasia/stromal expansion (yellow arrows) in SAMP6 LFD-fedmouse#80 (iii, iv).
These differences inperi-glandular fibrosisweremore evidentin SAMP6HFD-fed thanLFD-fedmicebutdidnotreach, statistical significance
(P ¼ 0.10).D: Photomicrographs (4, i, iii; 20, ii, iv) of SAMP6 LFD-fed mice (i, ii) mice demonstrate significantly higher levels of brown
adipose tissue (BAT) thanwhite adipose tissue (WAT) compared toHFD-fedmice (iii, iv) (P ¼ 0.005). Insets in ii andiv are at 40.Tissues are
shownfromSAMP6LFD-fedmouse#68andHFD-fedmouse#80.
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that obesity, T2DM, lower urinary tract fibrosis, and
urinary voiding dysfunction are inextricably and bio-
logically linked.
Both the human and mouse studies point to inflam-
mation as a common biological link between lower
urinary tract fibrosis, LUTD, obesity, and T2DM. Sev-
eral studies have shown that male LUTD is associated
with inflammation of the prostate, evident as prostatic
inflammatory infiltrate and/or prostatitis. Immuno-
histochemical studies examining the histopathology
of BPH have reported the presence of pervasive in-
flammatory infiltrate comprising leukocytes associat-
ed with acute inflammation, chronic inflammation,
or both. Inflammatory cells comprising neutrophillic
or lymphocytic infiltrates were identified in 90% of
transurethral resections of the prostate (TURP) speci-
mens from 80 patients diagnosed with BPH/LUTS
but no history of prostatitis or prostatic infection [24].
Chronic inflammatory infiltrate was also detected in
30–60% of 1,197 randomly selected men with BPH/
LUTS as part of the Medical Therapy of Prostatic
Symptoms (MTOPS) study. Patients with chronic in-
flammatory infiltrate had larger prostate volumes and
demonstrated significantly more clinical progression
and acute urinary retention than those with no evi-
dence of inflammation [25,26]. A study that prospec-
tively analyzed 167 autopsied prostates identified 93
glands harboring BPH/LUTS, and 75% of these dem-
onstrated inflammatory infiltrate (predominantly
chronic inflammation) compared to 50% of those
without BPH/LUTS and 55% of those with evidence
of cancer [27]. As originally reported by Theyer et al.
[28] and Steiner et al. [29] and recently summarized
by Kramer et al. [30], inflammatory infiltrates are very
commonly observed in BPH/LUTS specimens and
comprise 70% T-lymphocytes, 15% B cells, and 15%
macrophages, as well as mast cells. These studies
also showed that resident T-lymphocyte populations
in prostate tissues actively secrete a diverse array
of chemokines into the surrounding microenviron-
ment, including those known to strongly induce myo-
fibroblast differentiation and therefore potentiate
fibrosis.
Studies from our own laboratory have shown that
the aging human prostate is characterized by an in-
flammatory tissue microenvironment. CXCL8 (IL-8)
TABLE I. HistopathologicalCharacteristicsofMurineProstates
SAMP6
HFD
Dorsal prostate:
focal increase in
cellular stroma
Lateral prostate:
epithelial
hyperplasia
% Brown
adipose tissue
(BAT)
AKR/J
HFD
Dorsal prostate:
focal increase in
cellular stroma
Lateral prostate:
epithelial
hyperplasia
% Brown
adipose tissue
(BAT)
62 1.5 0.0 2 84 1.0 1.0 2
63 1.5 0.0 20 85 1.0 1.0 2
64 3.0 0.0 10 87 0.0 1.0 2
65 1.0 0.0 2 88 2.0 1.0 10
68 1.5 1.0 2 89 1.5 1.0 15
70 1.0 0.0 5 90 0.0 1.0 2
71 1.0 0.0 5 91 0.0 0.0 0
66 n.i. 0.0 2 82 n.i. 0.0 30
67 n.i. 0.0 2 83 n.i. 1.0 30
69 n.i. 0.0 20 86 n.i. 1.0 2
SAMP6
LFD
Dorsal prostate:
focal increase in
cellular stroma
Lateral prostate:
epithelial
hyperplasia
% Brown
adipose tissue
(BAT)
AKR/J
LFD
Dorsal prostate:
focal increase in
cellular stroma
Lateral prostate:
epithelial
hyperplasia
% Brown
adipose tissue
(BAT)
72 1.0 0.0 50 93 2.0 1.0 10
74 1.0 0.0 50 94 0.0 0.0 0
75 1.0 1.0 40 95 1.5 2.0 2
76 1.0 1.0 50 96 1.5 1.0 10
77 0.0 0.0 30 97 1.0 1.0 20
78 1.5 0.0 30 98 1.0 1.0 50
79 1.0 0.0 30 99 1.5 1.0 50
80 1.0 0.0 80
81 1.5 0.0 10
73 n.i. n.i. 5
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and a closely related CXC-type chemokine, CXCL5
(ENA-78), are secreted at significantly higher levels
by stromal fibroblasts cultured from the prostates of
older compared to younger men [31–33]. Moreover,
these and additional chemokines (CXCL1, CXCL6,
CXCL12) secreted by aging prostate stroma induced
proliferative responses from both epithelial and stro-
mal prostate cells in vitro [32,34,35]. Studies pub-
lished by the Rowley laboratory have shown that
myofibroblast-rich ‘‘reactive stroma’’ characterizes
hyperplastic, dysplastic, and neoplastic-associated
prostatic stroma [36,37], that BPH nodules exhibited
elevated epithelial CXCL8 immunoreactivity associat-
ed with reactive stroma [37], that CXCL8 was suffi-
cient for induction of a fibroblast to myofibroblast
transition [37], and that over-expression of KC, the
mouse homologue of CXCL8, in mouse prostatic epi-
thelium was sufficient to produce hyperplastic pros-
tate epithelial acini associated with a periacinar
reactive stroma [38].
In addition to low-level, but persistent, chronic in-
flammation and aging-associated inflammatory
changes in the tissue microenvironment, obesity like-
ly contributes significantly to inflammatory changes
in adjacent tissues. Obesity-mediated inflammatory
changes in the tissue microenvironment, or ‘‘metain-
flammation,’’ [39] include those produced by adipo-
cytes and resident macrophages in WAT. In addition
to triglyceride and lipid storage, WAT adipocytes se-
crete a medley of endocrine and paracrine factors,
collectively termed adipokines, which include inflam-
matory mediators such as interleukins, CC- and CXC-
type chemokines, and TGF-b [40,41]. As reported
here, significantly higher levels of WAT were evident
for HFD-fed compared to LFD-fed mice in association
with lower urinary tract fibrosis and urinary voiding
dysfunction.
The level and composition of inflammatory adipo-
kines is altered in obesity-associated WAT [41], and
some of these are known to activate the IKKb/NF-
kB pathway in adipocytes, hepatocytes, and associ-
ated macrophages. NF-kB is a powerful transcrip-
tion factor that mediates the expression of multiple
genes encoding inflammatory mediators, including
several interleukins, CC- and CXC-type chemokines,
and TGF-b [42,43]. TGF-b is a well-known pro-
fibrotic protein that promotes myofibroblast pheno-
conversion and tissue fibrosis [44,45]. A recent study
reported that adipose tissue from obese subjects con-
tained increased areas of fibrosis, which correlated
inversely with insulin and positively with macro-
phage number, compared to adipose tissue from
lean subjects. Although macrophages in crownlike
structures (CLS) were more abundant in obese adi-
pose tissue, the majority of macrophages were
associated with fibrosis and were not organized in
CLS. Macrophages in CLS were predominantly M1,
but most other macrophages, particularly those in
fibrotic areas, were M2. Moreover, TGF-b was more
abundant in M2 macrophages and was further in-
creased by coculture with adipocytes. Downstream
effectors of TGF-b, such as plasminogen activator in-
hibitor-1, collagen VI, and phosphorylated Smad,
were increased in macrophages and adipocytes.
Thus, adipose tissue of insulin-resistant humans
demonstrated increased fibrosis, M2 macrophage
abundance, and TGF-b activity [46]. Recent
studies from our research group show that
several CXC-type chemokines, notably CXCL5,
CXCL8, and CXCL12, can mediate myofibroblast
phenoconversion and accumulation in the absence
of TGF-b [47]. Taken together, these studies
suggest that inflammatory changes in the tissue
microenvironment brought about through low level
but chronic infiltration by the innate immune sys-
tem, aging, and/or obesity may be sufficient to pro-
mote myofibroblast phenoconversion, accumulation,
and fibrosis in affected tissues, including those of
the lower urinary tract.
The studies reported here utilized the SAMP
mouse model, which was developed through inbreed-
ing of AKR/J mice as a model of spontaneous senes-
cence in mice. The aging pattern in this model is
considered to be due to an accelerated senescence
rather than to premature aging or senescence [19,48].
An early study noted that the most striking histologi-
cal changes in SAMP6 mouse prostates were stromal
hyperplasia and inflammation in the dorsal prostate
at age 15 months [19]. Moreover, regular mouse
chow-fed SAMP6 mice exhibit higher levels of plasma
glucose, triglyceride, insulin, and leptin levels and he-
patic lipid levels, but lower levels of plasma glucagon
and adiponectin, than age-matched AKR/J mice [20].
These observations suggest that SAMP6 mice may be
predisposed to developing hyperglycemia and insulin
resistance consistent with T2DM. Indeed, the results
of the studies reported here support this conclusion
and show that HFD-fed SAMP6 mice exhibited higher
levels of hyperglycemia and insulin resistance concur-
rent with worse lower urinary tract fibrosis and dys-
function compared to HFD-fed AKR/J mice.
In summary, the studies reported here demonstrate
the acquisition of urinary voiding dysfunction con-
current with obesity-induced T2DM and lower uri-
nary tract fibrosis in a mouse model. This model
recapitulates several epidemiological studies of hu-
man populations that associate obesity, metabolic
syndrome, and T2DM with urinary voiding dysfunc-
tion. Therefore, further studies using these mouse
models may provide the means to delineate the
Obesity,Diabetes,UrinaryVoiding 1131
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cellular mechanisms that biologically couple lower
urinary tract fibrosis and urinary voiding dysfunction
with obesity-induced T2DM.
ACKNOWLEDGMENTS
We would like to thank Dr. Jeremy Adler for his
help assessing lower urinary tract tissues collagen
content. This work was funded by the National Insti-
tutes of Health (NIH)/National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) Award
P20DK090770 (J.A.M.) and by the Michigan Institute
for Clinical & Health Research (MICHR) NIH Clinical
& Translational Science Award (CTSA) UL1RR024986
(M.G.-K.).
REFERENCES
1. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk
factors for clinical benign prostatic hyperplasia in a communi-
ty-based population of healthy aging men. J Clin Epidemiol
2001;54(9):935–944.
2. Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J,
Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski
A, Chappel CR, Costello A, Dobronski P, Farmer RD,
Jimenez Cruz F, Jonas U, MacRae K, Pientka L, Rutten FF, van
Schayck CP, Speakman MJ, Tiellac P, Tubaro A, Vallencien G,
Vela Navarrete R. Incidence and prevalence of lower urinary
tract symptoms suggestive of benign prostatic hyperplasia
in primary care—The Triumph project. Eur Urol 2002;42(4):
323–328.
3. Guess HA. Benign prostatic hyperplasia: Antecedents and
natural history. Epidemiol Rev 1992;14:131–153.
4. McVary KT. A review of combination therapy in patients with
benign prostatic hyperplasia. Clin Ther 2007;29(3):387–398.
5. Garber AJ. Obesity and type 2 diabetes: Which patients are at
risk? Diabetes Obes Metab 2012;14(5):399–408.
6. Centers for Disease Control and Prevention National Diabetes
Fact Sheet: National estimates and general information on
diabetes and prediabetes in the United States 2011. Atlanta,
GA: US Department of Health and Human; Services, Centers
for Disease Control and Prevention; 2011.
7. Parsons JK. Benign prostatic hyperplasia and male lower uri-
nary tract symptoms: Epidemiology and risk factors. Curr
Bladder Dysfunct Rep 2010;5(4):212–218.
8. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign
prostatic hyperplasia: Clinical connections, emerging etiologi-
cal paradigms and future directions. J Urol 2013;189(1 Suppl):
S102–S106.
9. Khoo J, Piantadosi C, Duncan R, Worthley SG, Jenkins A,
Noakes M, Worthley MI, Lange K, Wittert GA. Comparing
effects of a low-energy diet and a high-protein low-fat diet on
sexual and endothelial function, urinary tract symptoms, and
inflammation in obese diabetic men. J Sex Med 2011;8(10):
2868–2875.
10. Klein BE, Klein R, Lee KE, Bruskewitz RC. Correlates of
urinary symptom scores in men. Am J Public Health 1999;
89(11):1745–1748. PMCID: 1508982.
11. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL,
Taylor JM, James SA, Cooney KA, Doerr KM, Montie JE, Schot-
tenfeld D. Risk factors for lower urinary tract symptoms in a
population-based sample of African-American men. Am J
Epidemiol 2003;157(10):906–914.
12. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel
M. Effect of diabetes on lower urinary tract symptoms in
patients with benign prostatic hyperplasia. J Urol 2000;163(6):
1725–1729.
13. Koskimaki J, Hakama M, Huhtala H, Tammela TL. Association
of non-urological diseases with lower urinary tract symptoms.
Scand J Urol Nephrol 2001;35(5):377–381.
14. Dib PT, Trigo-Rocha F, Gomes CM, Srougi M. Urodynamic
evaluation in diabetic patients with prostate enlargement
and lower urinary tract symptoms. Urol Int 2008;80(4):378–
382.
15. Sarma AV, Burke JP, Jacobson DJ, McGree ME, St Sauver J,
Girman CJ, Lieber MM, Herman W, Macoska J, Montie JE,
Jacobsen SJ. Associations between diabetes and clinical
markers of benign prostatic hyperplasia among community-
dwelling Black and White men. Diabetes Care 2008;31(3):
476–482.
16. Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler
J, Arruda EM, Macoska JA. Prostatic fibrosis is associated with
lower urinary tract symptoms. J Urol 2012;188(4):1375–1381.
PMCID: 3485634.
17. Takeda T, Hosokawa M, Higuchi K. Senescence-accelerated
mouse (SAM): A novel murine model of senescence. Exp
Gerontol 1997;32(1–2):105–109.
18. Takeda T, Matsushita T, Kurozumi M, Takemura K, Higuchi
K, Hosokawa M. Pathobiology of the senescence-accelerated
mouse (SAM). Exp Gerontol 1997;32(1–2):117–127.
19. Sugimura Y, Sakurai M, Hayashi N, Yamashita A, Kawamura
J. Age-related changes of the prostate gland in the senescence-
accelerated mouse. Prostate 1994;24(1):24–32.
20. Niimi K, Takahashi E, Itakura C. Adiposity-related biochemi-
cal phenotype in senescence-accelerated mouse prone 6
(SAMP6). Comp Med 2009;59(5):431–436. PMCID: 2771603.
21. Hodges SJ, Zhou G, Deng FM, Aboushwareb T, Turner C,
Andersson KE, Santago P, Case D, Sun TT, Christ GJ. Voiding
pattern analysis as a surrogate for cystometric evaluation in
uroplakin II knockout mice. J Urol 2008;179(5):2046–2051.
22. Adler J, Swanson SD, Schmiedlin-Ren P, Higgins PD,
Golembeski CP, Polydorides AD, McKenna BJ, Hussain HK,
Verrot TM, Zimmermann EM. Magnetization transfer helps
detect intestinal fibrosis in an animal model of Crohn disease.
Radiology 2011;259(1):127–135. PMCID: 3064818.
23. Adler, Imatinib decreases bowel wall fibrosis, reduces inflam-
matory cytokines and pro-fibrotic factors in peptidoglican-
polysaccharide rat model of Crohn’s disease. 2010.
24. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflam-
mation and/or infection in benign prostatic hyperplasia. BJU
Int 1999;84(9):976–981.
25. Roehrborn C, Kaplan S, Noble W, Lucia M, Slawin K, McVary
K, Kusek J, Nyberg L. The impact of acute or chronic inflam-
mation in baseline biopsy on the risk of clinical progression of
BPE: Results from the MTOPS study. AUA Meeting. 2005; Ab-
stract # 1277.
26. Robert G, Descazeaud A, Nicolaı¨ew N, Terry S, Sirab N,
Vacherot F, Maille´ P, Allory Y, de la Taille A. Inflammation in
benign prostatic hyperplasia: A 282 patients’ immunohisto-
chemical analysis. Prostate 2009;69(16):1774–1780.
27. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sun-
heimer R, Threatte G, Jumbelic M, Haas GP. Evaluation of
prostatitis in autopsied prostates–is chronic inflammation
1132 Gharaee-Kermaniet al.
The Prostate
more associated with benign prostatic hyperplasia or cancer?
J Urol 2008;179(5):1736–1740. PMCID: 2661538.
28. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W,
Marberger M, Zechner O, Steiner GE. Phenotypic characteriza-
tion of infiltrating leukocytes in benign prostatic hyperplasia.
Lab Invest 1992;66(1):96–107.
29. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reith-
mayr F, Paikl D, Ecker RC, Hrachowitz K, Kramer G, Lee C,
Marberger M. Cytokine expression pattern in benign prostatic
hyperplasia infiltrating T cells and impact of lymphocytic
infiltration on cytokine mRNA profile in prostatic tissue. Lab
Invest 2003;83(8):1131–1146.
30. Kramer G, Mitteregger D, Marberger M. Is benign prostatic
hyperplasia (BPH) an immune inflammatory disease? Eur Urol
2007;51(5):1202–1216.
31. Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA.
CXCL12 overexpression and secretion by aging fibroblasts en-
hance human prostate epithelial proliferation in vitro. Aging
Cell 2005;4(6):291–298.
32. Begley LA, Kasina S, MacDonald J, Macoska JA. The inflamma-
tory microenvironment of the aging prostate facilitates cellular
proliferation and hypertrophy. Cytokine 2008;43(2):194–199.
PMCID: 2538565.
33. Macoska JA. Chemokines and BPH/LUTS. Differentiation
2011;82(4–5):253–260.
34. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro
RJ, Chinnaiyan AM, Macoska JA. CXCL5 promotes prostate
cancer progression. Neoplasia 2008;10(3):244–254. PMCID:
2262133.
35. Begley LA, MacDonald JW, Day ML, Macoska JA. CXCL12
activates a robust transcriptional response in human prostate
epithelial cells. J Biol Chem 2007;282(37):26767–26774.
36. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley
DR. Reactive stroma in human prostate cancer: induction of
myofibroblast phenotype and extracellular matrix remodeling.
Clin Cancer Res 2002;8(9):2912–2923.
37. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR.
Elevated epithelial expression of interleukin-8 correlates with
myofibroblast reactive stroma in benign prostatic hyperplasia.
Urology 2008;72(1):205–213.
38. Schauer IG, Ressler SJ, Rowley DR. Keratinocyte-derived che-
mokine induces prostate epithelial hyperplasia and reactive
stroma in a novel transgenic mouse model. Prostate 2009;
69(4):373–384.
39. Lumeng CN, Saltiel AR. Inflammatory links between obesity
and metabolic disease. J Clin Invest 2011;121(6):2111–2117.
40. Harwood HJ Jr. The adipocyte as an endocrine organ in the
regulation of metabolic homeostasis. Neuropharmacology
2012;63(1):57–75.
41. Taube A, Schlich R, Sell H, Eckardt K, Eckel J. Inflammation
and metabolic dysfunction: Links to cardiovascular diseases.
Am J Physiol Heart Circ Physiol 2012;302(11):H2148–H2165.
42. Pahl HL. Activators and target genes of Rel/NF-kappaB tran-
scription factors. Oncogene 1999;18(49):6853–6866.
43. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin re-
sistance. J Clin Invest 2006;116(7):1793–1801. PMCID: 1483173.
44. Scotton CJ, Chambers RC. Molecular targets in pulmonary
fibrosis: The myofibroblast in focus. Chest 2007;132(4):1311–
1321.
45. Wynn TA. Cellular and molecular mechanisms of fibrosis.
J Pathol 2008;214(2):199–210.
46. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM,
Zhu B, Peterson CA, Kern PA. Adipose tissue macrophages in
insulin-resistant subjects are associated with collagen VI and
fibrosis and demonstrate alternative activation. Am J Physiol
Endocrinol Metab 2010;299(6):E1016–E1027.
47. Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R,
Macoska JA. CXC-type chemokines promote myofibroblast
phenoconversion and prostatic fibrosis. PLoS ONE 2012;7(11):
e49278.
48. Lecka-Czernik B, Moerman EJ, Shmookler Reis RJ, Lipschitz
DA. Cellular and molecular biomarkers indicate precocious in
vitro senescence in fibroblasts from SAMP6 mice. Evidence
supporting a murine model of premature senescence and
osteopenia. J Gerontol A Biol Sci Med Sci 1997;52(6):B331–
B336.
Obesity,Diabetes,UrinaryVoiding 1133
The Prostate
